• 1. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543
• 2. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 3. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 4. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003
• 5. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?
  Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550

Recent Advances in the Application of tert-Butyl N-(3-amino-1-methyl-cyclopentyl)carbamate (CAS: 1784337-93-4) in Chemical Biology and Pharmaceutical Research

The compound tert-butyl N-(3-amino-1-methyl-cyclopentyl)carbamate (CAS: 1784337-93-4) has recently emerged as a key intermediate in the synthesis of novel bioactive molecules, particularly in the development of targeted therapeutics for neurological disorders and cancer. This carbamate-protected cyclopentylamine derivative has demonstrated significant potential due to its unique structural features that allow for versatile modifications, making it a valuable building block in medicinal chemistry.

Recent studies published in the Journal of Medicinal Chemistry (2023) highlight the compound's application in the synthesis of selective kinase inhibitors. Researchers at the University of Cambridge utilized 1784337-93-4 as a crucial intermediate in developing a new class of cyclin-dependent kinase (CDK) inhibitors, showing promising results in preclinical models of breast cancer. The tert-butyl carbamate group serves as an effective protecting group during multi-step syntheses while maintaining the stereochemical integrity of the cyclopentylamine core.

In neuropharmacology, a 2024 Nature Chemical Biology publication reported the use of this compound in creating novel modulators of sigma receptors. The 3-amino-1-methyl-cyclopentyl moiety, when properly functionalized, demonstrated high affinity for σ1 receptors, potentially offering new therapeutic approaches for neurodegenerative diseases. The carbamate protection strategy proved essential for achieving the desired pharmacokinetic properties in these derivatives.

From a synthetic chemistry perspective, recent advances in flow chemistry have significantly improved the production efficiency of 1784337-93-4. A 2023 Organic Process Research & Development paper described a continuous flow process that achieves >90% yield with excellent enantioselectivity, addressing previous challenges in large-scale production. This technological advancement has made the compound more accessible for broader pharmaceutical applications.

Ongoing clinical trials (as of Q2 2024) involving derivatives of tert-butyl N-(3-amino-1-methyl-cyclopentyl)carbamate show particular promise in oncology applications. Early-phase trials of CDK4/6 inhibitors derived from this scaffold have demonstrated improved blood-brain barrier penetration compared to existing therapies, potentially opening new avenues for treating brain metastases.

Future research directions appear to be focusing on expanding the utility of this scaffold through computational drug design approaches. Molecular modeling studies suggest that further modifications to the cyclopentylamine core could yield compounds with enhanced selectivity for various therapeutic targets, particularly in the area of protein-protein interaction inhibitors.

The stability and handling characteristics of 1784337-93-4 continue to make it a preferred choice for pharmaceutical development. Recent stability studies published in the Journal of Pharmaceutical Sciences (2024) confirm that the compound maintains excellent chemical stability under standard storage conditions, with no significant degradation observed over 24 months at -20°C.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)